Literature DB >> 23839165

Current challenges in travelers' malaria.

Patricia Schlagenhauf1, Eskild Petersen.   

Abstract

Travel health providers are often confronted with complex scenarios when advising travelers on malaria prevention. Current challenges in prevention include malaria risk assessment, where a detailed itinerary and knowledge of malaria epidemiology are needed. Up-to-date information on the correct use, limitations, and drug interactions of current priority chemoprophylaxis agents (atovaquone/proguanil, mefloquine, doxycycline) is key. Another challenge is to identify and reach travelers who are most at risk of malaria, such as the traveler visiting friends and relatives. Posttravel, delays in presentation, diagnosis, and inappropriate treatment of malaria are key risk factors leading to death. Treatment of malaria is an emergency requiring expert in-patient management and referral to a center with adequate expertise. Artemisinin combination therapies are the drugs of choice for uncomplicated malaria. Complicated malaria is treated preferably with intravenous artesunate, and the supply and quality of this life-saving antimalarial in some settings can pose one of the most urgent challenges in travelers' malaria.

Entities:  

Year:  2013        PMID: 23839165     DOI: 10.1007/s11908-013-0343-3

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  37 in total

Review 1.  Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster.

Authors: 
Journal:  Trans R Soc Trop Med Hyg       Date:  2000-04       Impact factor: 2.184

2.  Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia.

Authors:  W R Taylor; H Widjaja; T L Richie; H Basri; C Ohrt; E Taufik; T R Jones; K C Kain; S L Hoffman
Journal:  Am J Trop Med Hyg       Date:  2001 May-Jun       Impact factor: 2.345

Review 3.  Coartemether (artemether and lumefantrine): an oral antimalarial drug.

Authors:  Walther H Wernsdorfer
Journal:  Expert Rev Anti Infect Ther       Date:  2004-04       Impact factor: 5.091

Review 4.  Plasmodium knowlesi: the emerging zoonotic malaria parasite.

Authors:  Spinello Antinori; Laura Galimberti; Laura Milazzo; Mario Corbellino
Journal:  Acta Trop       Date:  2012-10-23       Impact factor: 3.112

5.  Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia.

Authors:  Thierry Rolling; Stefan Schmiedel; Dominic Wichmann; Dieter Wittkopf; Gerd-Dieter Burchard; Jakob P Cramer
Journal:  Malar J       Date:  2012-05-17       Impact factor: 2.979

6.  Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.

Authors:  Arjen M Dondorp; Caterina I Fanello; Ilse C E Hendriksen; Ermelinda Gomes; Amir Seni; Kajal D Chhaganlal; Kalifa Bojang; Rasaq Olaosebikan; Nkechinyere Anunobi; Kathryn Maitland; Esther Kivaya; Tsiri Agbenyega; Samuel Blay Nguah; Jennifer Evans; Samwel Gesase; Catherine Kahabuka; George Mtove; Behzad Nadjm; Jacqueline Deen; Juliet Mwanga-Amumpaire; Margaret Nansumba; Corine Karema; Noella Umulisa; Aline Uwimana; Olugbenga A Mokuolu; Olanrewaju T Adedoyin; Wahab B R Johnson; Antoinette K Tshefu; Marie A Onyamboko; Tharisara Sakulthaew; Wirichada Pan Ngum; Kamolrat Silamut; Kasia Stepniewska; Charles J Woodrow; Delia Bethell; Bridget Wills; Martina Oneko; Tim E Peto; Lorenz von Seidlein; Nicholas P J Day; Nicholas J White
Journal:  Lancet       Date:  2010-11-07       Impact factor: 79.321

7.  Prozone in malaria rapid diagnostics tests: how many cases are missed?

Authors:  Philippe Gillet; Annelies Scheirlinck; Jocelijn Stokx; Anja De Weggheleire; Hélder S Chaúque; Oreana D J V Canhanga; Benvindo T Tadeu; Carla D D Mosse; Armindo Tiago; Samuel Mabunda; Cathrien Bruggeman; Emmanuel Bottieau; Jan Jacobs
Journal:  Malar J       Date:  2011-06-15       Impact factor: 2.979

8.  Laboratory demonstration of a prozone-like effect in HRP2-detecting malaria rapid diagnostic tests: implications for clinical management.

Authors:  Jennifer Luchavez; Joanne Baker; Sheila Alcantara; Vicente Belizario; Qin Cheng; James S McCarthy; David Bell
Journal:  Malar J       Date:  2011-09-29       Impact factor: 2.979

9.  Acute and potentially life-threatening tropical diseases in western travelers--a GeoSentinel multicenter study, 1996-2011.

Authors:  Mogens Jensenius; Pauline V Han; Patricia Schlagenhauf; Eli Schwartz; Philippe Parola; Francesco Castelli; Frank von Sonnenburg; Louis Loutan; Karin Leder; David O Freedman
Journal:  Am J Trop Med Hyg       Date:  2013-01-16       Impact factor: 2.345

10.  Malaria risk in travelers.

Authors:  Helena Hervius Askling; Jenny Nilsson; Anders Tegnell; Ragnhild Janzon; Karl Ekdahl
Journal:  Emerg Infect Dis       Date:  2005-03       Impact factor: 6.883

View more
  3 in total

1.  Fifty years after the eradication of Malaria in Italy. The long pathway toward this great goal and the current health risks of imported malaria.

Authors:  Mariano Martini; Andrea Angheben; Niccolò Riccardi; Davide Orsini
Journal:  Pathog Glob Health       Date:  2021-03-18       Impact factor: 2.894

2.  Effects of a malaria elimination program: a retrospective study of 623 cases from 2008 to 2013 in a Chinese county hospital near the China--Myanmar border.

Authors:  Xinyu Wang; Linlin Yang; Tao Jiang; Bingyan Zhang; Shuqing Wang; Xingfen Wu; Tianying Wang; Yanlin Li; Min Liu; Quanbang Peng; Wenhong Zhang
Journal:  Emerg Microbes Infect       Date:  2016-01-20       Impact factor: 7.163

3.  Analysis of Epidemiological Changes and Prevention Effects for Malaria in Weifang, Shandong Province, China from 1957 to 2017.

Authors:  Xiao Song; Qiqi Shi; Chongxing Zhang; Xiangli Kong; Yeyuan Lv; Haifang Wang; Hongmei Liu; Lijuan Liu; Xiuxia Guo; Jingxuan Kou; Xiaodan Huang; Huaiwei Wang; Peng Cheng; Maoqing Gong
Journal:  Iran J Public Health       Date:  2020-10       Impact factor: 1.429

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.